Our Science
Think Outside the Brain
From overturning the old dogma to a new therapeutic approach for neurodegeneration
01 | Scientific foundation
Prof. Michal Schwartz challenged the old dogma
The brain was long viewed as largely immune-isolated. Her research helped establish a fundamentally different paradigm: the brain depends on regulated support from the peripheral immune system for maintenance, resilience and repair.
From the brain immune privilege to privileged immunity of the brain
Old dogma
The brain is completely isolated from the immune system
- Lymphatic-like vessels in meninges (ignored)1787
- The brain is physically isolated1885
Blood-Brain-Barrier - The brain is functionally isolated1948
Immune privilege
Contemporary understanding
The brain is NOT isolated from the immune system
- Peripheral immune cells (protective autoimmunity; T cell and monocyte-derived macrophages) support CNS repair1998/1999
- Brain functional plasticity is tightly dependent on the immune system2004/2006
- Meningeal and blood-cerebrospinal barriers serve as immunological niches and gateways2013
- The brain is equipped with structural and functional lymphatic system2015
This discovery is the scientific foundation of Immunobrain. Rather than treating peripheral immunity as a threat to be excluded from the CNS, our approach is built on restoring a physiological brain-immune dialogue that becomes impaired with aging and neurodegenerative disease.
Sources: Schwartz, Neuron, 2026 (source of scheme); Castellani, Croese, Peralta Ramos & Schwartz, Science, 2023; Schwartz et al., Neuron, 2022.
02 | Brain-immune ecosystem
The brain relies on peripheral immunity
Peripheral immune cells support brain maintenance remotely and can be recruited through specialized CNS interfaces when repair is needed.
The key implication is that brain repair is not performed by resident cells alone. CNS borders, meninges and the choroid plexus provide regulated routes for immune communication and selective recruitment of protective peripheral cells.
Sources: Croese, Castellani & Schwartz, Nature Immunology, 2021; Castellani et al., Science, 2023.
03 | What changes with aging
Aging disrupts both the brain and the periphery
Neurodegeneration develops in the setting of chronic brain inflammation and declining peripheral immune competence.
With aging, microglia can acquire dysfunctional and senescent states while peripheral immunity becomes less capable of mounting an effective repair response. The result is a failure to resolve inflammation, increasing vulnerability of synapses and neurons.
Sources: Baruch, Deczkowska et al., Science, 2014; Deczkowska et al., Nature Communications, 2017.
Alzheimer's disease progression is driven by neuroinflammation and systemic immune aging
Immunobrain
Rejuvenation of the immune system renews brain-immune dialogue, facilitates the homing of immune-repairing cells that clear senescent microglia, and resolves inflammation. It can rescue dysfunctional neurons, providing neuroprotection.
04 | Why peripheral macrophages matter
Resident microglia and recruited macrophages are not redundant
Macrophages are essential for brain repair: a central insight from the Schwartz laboratory is that resident microglia alone may be insufficient for repair under pathological conditions.
Monocyte-derived macrophages originate outside the brain and can be recruited when repair is required. Once recruited, they can display scavenging and inflammation-resolving properties that are distinct from resident microglia. This provides the biological rationale for therapeutically mobilizing peripheral immunity rather than simply suppressing inflammation inside the brain.
Sources: Shechter et al., PLoS Medicine, 2009.
05 | Why anti-PD-L1
Use an immune checkpoint as a temporary switch
The PD-1/PD-L1 pathway restrains T-cell activity. Transient checkpoint blockade can briefly release that brake and initiate a coordinated peripheral repair response.
The goal is not chronic immune activation. Preclinical work showed that a brief checkpoint-blocking signal can trigger downstream events that outlast antibody exposure. In this model, anti-PD-L1 acts as an instructor: it initiates the immune cascade, while recruited cells execute the repair response in the CNS.
Sources: Baruch et al., Nature Medicine, 2016.
06 | Mechanistic proof
The anti-PD-L1 beneficial effect depends on monocyte-derived macrophage recruitment
Checkpoint blockade promotes brain homing of monocytes and Tregs, and blocking the monocyte recruitment pathway removes the beneficial effect.
This is a critical mechanistic link: the response is not explained simply by peripheral T-cell activation. CCR2-dependent monocyte recruitment is required for the downstream CNS effects, identifying monocyte-derived macrophage recruitment as a key mediator of the beneficial effect.
Sources: Ben-Yehuda et al., Molecular Neurodegeneration, 2021; Raposo et al., Journal of Neuroscience, 2014.
07 | TREM2 independence
Anti-PD-L1 beneficial effect bypasses TREM2 polymorphism through monocyte-derived macrophage recruitment
A major implication of the macrophage-driven mechanism is that benefit is not dependent on intact TREM2 signaling in resident microglia.
In 5xFAD models, anti-PD-L1 improved behavioral outcomes in both Trem2+/+ and Trem2-/- backgrounds. Together with the CCR2 experiments, this supports a model in which recruited monocyte-derived macrophages can provide a complementary repair pathway when resident microglial function is compromised.
Sources: Dvir-Szternfeld, Castellani, Arad et al. & Schwartz, Nature Aging, 2022.
08 | What happens inside the brain
Recruited macrophages facilitate the removal of senescent microglia and reduce inflammation
The downstream response includes clearance of senescent microglia, reduced inflammatory signaling and preservation of synaptic function.
These findings connect the peripheral immune trigger to the CNS outcome: recruited immune cells alter the microglial landscape and help resolve chronic neuroinflammation, followed by downstream effects on synaptic and neuronal integrity.
Sources: Rachmian et al. & Schwartz, Nature Neuroscience, 2024; Rosenzweig et al. & Schwartz, Nature Communications, 2019.
09 | Translation into IBC-Ab002
IBC-Ab002 is engineered based on the mechanism of action in animal models of dementia
A fully human anti-PD-L1 designed for transient, controlled peripheral immune activation rather than continuous checkpoint inhibition.
IBC-Ab002 combines high-affinity PD-L1 binding with Fc modification eliminating ADCC/CDC and a short half-life designed to limit prolonged systemic exposure. The therapeutic concept is intermittent dosing: a short peripheral immune signal that initiates a longer-lived repair response.
References
- Baruch, Deczkowska et al., Science, 2014.
- Baruch et al., Nature Medicine, 2016.
- Ben-Yehuda et al., Molecular Neurodegeneration, 2021.
- Castellani, Croese, Peralta Ramos & Schwartz, Science, 2023.
- Croese, Castellani & Schwartz, Nature Immunology, 2021.
- Deczkowska et al., Nature Communications, 2017.
- Dvir-Szternfeld, Castellani, Arad et al. & Schwartz, Nature Aging, 2022.
- Rachmian et al. & Schwartz, Nature Neuroscience, 2024.
- Raposo et al., Journal of Neuroscience, 2014.
- Rosenzweig et al. & Schwartz, Nature Communications, 2019.
- Schwartz, Neuron, 2026.
- Schwartz et al., Neuron, 2022.
- Shechter et al., PLoS Medicine, 2009.
